Compositions and methods for removing bio-synthetic nano-particles from bodily fluids

Patent metadata

Field	Value
Publication number	US-12161765-B2
Application number	US-202217692289-A
Country	US
Kind code	B2
Filing date	Mar 11, 2022
Priority date	Mar 11, 2021
Publication date	Dec 10, 2024
Grant date	Dec 10, 2024

Abstract

Bait and capture methods and compositions for removing bio-synthetic nano-particles from body fluids. Bio-synthetic nano-particles are baited with one-half of a bait and capture complex and lyophilized. The baited bio-synthetic nano-particle is reconstituted and administered to a subject for diagnostic or therapeutic purposes. To remove the bio-synthetic nano-particle from the body, the body fluid containing the baited bio-synthetic nano-article is contacted with the capture portion of the bait and capture complex. The body fluid from which the bio-synthetic nano-particles have been removed may be returned to the subject.

First claim

The invention claimed is:

1. A method for removing a nano-particle from a bodily fluid comprising: complexing an adamantane compound to a nano-particle, administering to a subject the nano-particle complexed to said adamantane compound, and subsequently contacting the bodily fluid with mono-6-O-(p-toluenesulfonyl)-β-cyclodextrin functionalized polystyrene beads, to remove said nano-particle complexed to said adamantane compound from said bodily fluid, wherein the adamantane compound has the formula:

2. A method according to claim 1 wherein the nano-particle is a synthetic oxygen-carrier substitute and the bodily fluid is whole blood.

3. The method according to claim 1 , further comprising lyophilizing a result of said complexing step for packaging and transport, and reconstituting a result of said lyophilizing step prior to said administering step.

4. The method of claim 1 , wherein adamantane functional groups of said adamantane compound are located on a surface of the nano-particle.

5. The method of claim 1 , wherein the nano-particle is a synthetic oxygen carrier substitute.

6. The method of claim 1 , wherein functional groups of said adamantane compound are located on a surface of the nano-particle.

Assignees

• Kalocyte Inc
• Univ Maryland
• Univ Maryland

Inventors

• Pan Dipanjan
• Doctor Allan
• Mittal Nivesh

Classifications

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61F2/064

  with special features to facilitate anastomotic coupling (anastomosis of natural blood vessels A61B17/11) · CPC title

• A61M1/3687

  Chemical treatment (A61M1/3675 takes precedence) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title